<?xml version="1.0" encoding="UTF-8"?>
<p id="Par11">Arbidol (umifenovir) is a broad-spectrum antiviral compound approved in Russia and China for prophylaxis and treatment of influenza. This compound shows activities against numerous DNA and RNA viruses [
 <xref ref-type="bibr" rid="CR27">27</xref>]. Arbidol was found to be effective to SARS-CoV-2 in vitro [
 <xref ref-type="bibr" rid="CR28">28</xref>]. Arbidol is available in oral dosage forms in China and Russia [
 <xref ref-type="bibr" rid="CR29">29</xref>]. The dosage regimen of arbidol (0.2 g every time, twice daily, not be given over 10 days) in adults with COVID-19 was recommended [
 <xref ref-type="bibr" rid="CR1">1</xref>]. There is no recommendation of dosage regimen of arbidol in children with COVID-19 so far.
</p>
